Leflunomide, a reversible monoamine oxidase inhibitor.
Potchefstroom, South Africa. In Cent Nerv Syst Agents Med Chem, 24 Sep 2015
UNASSIGNED: A screening study aimed at identifying inhibitors of the enzyme, monoamine oxidase (MAO), among clinically used drugs have indicated that the antirheumatic drug, leflunomide, is an inhibitor of both MAO isoforms.
Inhibition and oxygen activation in copper amine oxidases.
Bozeman, United States. In Acc Chem Res, Jun 2015
Inhibition of these enzymes by antifungal or antiprotozoal agents, as well as classic monoamine oxidase (MAO) inhibitors, may contribute to the adverse side effects associated with drug treatment.
[Current state and potential of pharmacogenetic studies in the treatment of depression].
In Zh Nevrol Psikhiatr Im S S Korsakova, Dec 2014
The following sections of the review are devoted to the above issues: adrenoreceptors, serotonin transporter protein, dopamine transporter protein, monoamine oxidase A, catechol-O-methyltransferase, brain-derived neurotrophic factor, the hypothalamic-pituitary-adrenal system, G-proteins, the glutamatergic system.
Pharmacological treatment of Parkinson disease: a review.
Hamilton, Canada. In Jama, May 2014
RESULTS: Although levodopa is the most effective medication available for treating the motor symptoms of Parkinson disease, in certain instances (eg, mild symptoms, tremor as the only or most prominent symptom, aged <60 years) other medications (eg, monoamine oxidase type B inhibitors [MAOBIs], amantadine, anticholinergics, β-blockers, or dopamine agonists) may be initiated first to avoid levodopa-related motor complications.